Cantor Fitzgerald Estimates PVLA FY2024 Earnings

Palvella Therapeutics (NASDAQ:PVLA) – Research analysts at Cantor Fitzgerald issued their FY2024 earnings per share (EPS) estimates for Palvella Therapeutics in a research report issued to clients and investors on Wednesday, December 18th. Cantor Fitzgerald analyst J. Schimmer anticipates that the company will earn ($3.02) per share for the year. Cantor Fitzgerald currently has a “Overweight” rating on the stock.

Palvella Therapeutics Trading Up 0.4 %

Shares of PVLA opened at $12.05 on Friday. Palvella Therapeutics has a one year low of $6.20 and a one year high of $22.32.

Insider Transactions at Palvella Therapeutics

In other news, Director George M. Jenkins acquired 4,000 shares of the business’s stock in a transaction that occurred on Wednesday, December 18th. The stock was purchased at an average cost of $12.93 per share, for a total transaction of $51,720.00. Following the completion of the transaction, the director now owns 180,671 shares in the company, valued at approximately $2,336,076.03. This trade represents a 2.26 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.